Two meta-analyses, one of them from the American Gastroenterological Association (AGA), found that GI symptoms and liver abnormalities are not uncommon in patients with COVID-19. The AGA issued a series of best practice statements based on its findings.
About 84% of participants randomly assigned to receive rifabutin in addition to amoxicillin and omeprazole achieved Helicobacter pylori eradication, compared to 58% of those who received amoxicillin and omeprazole alone.
Women have a significantly lower risk of developing nonalcoholic fatty liver disease (NAFLD) but a higher risk of developing advanced fibrosis from NAFLD, according to a systematic review and meta-analysis.
A 37-year-old man is evaluated during a follow-up appointment after resection of a well-differentiated adenocarcinoma of the ascending colon. His family history is significant for endometrial cancer in his mother and colon cancer in his maternal grandfather. What is the most appropriate next step in management?
In the past month, the U.S. Preventive Services Task Force published a draft recommendation statement on screening for hepatitis B virus (HBV) infection, and two systematic reviews and meta-analyses looked at treatments and a novel immunoassay to quantify HBV DNA.
Recommendations from the American Gastroenterological Association and the Joint Task Force for Allergy-Immunology Practice Parameters cover use of proton-pump inhibitors, steroids, diets, and endoscopic dilation.
Patients were significantly more likely to report that their postprandial distress syndrome “extremely improved” or “improved” if they received acupuncture for 12 weeks rather than a sham treatment, a Chinese study found.
A small number of patients experienced balloon hyperinflation and acute pancreatitis with the Orbera and ReShape liquid-filled intragastric balloons.
A new kinase inhibitor, ripretinib, is now indicated to treat adults with advanced GI stromal tumors who have previously received three or more kinase inhibitor therapies, including imatinib.
While fecal microbiota transplantation was effective in patients with moderate to severe irritable bowel syndrome in a randomized trial, long-term risks of the therapy remain uncertain, an ACP Journal Club commentary noted.